Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation
Status: Enrolling
Updated:  8/29/2012
Bellevue Hospital Center
mi
from
New York, NY
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation
Status: Enrolling
Updated: 8/29/2012
Bellevue Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation
Status: Enrolling
Updated:  8/29/2012
Tisch Hospital
mi
from
New York, NY
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation
Status: Enrolling
Updated: 8/29/2012
Tisch Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Status: Enrolling
Updated:  10/4/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Status: Enrolling
Updated: 10/4/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
Status: Enrolling
Updated:  11/6/2012
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
Status: Enrolling
Updated: 11/6/2012
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Alabama School of Medicine
mi
from
Birmingham, AL
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Alabama School of Medicine
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of California Medical Center At Irvine-Orange
mi
from
Irvine, CA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of California Medical Center At Irvine-Orange
mi
from
Irvine, CA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Med College of Georgia
mi
from
Augusta, GA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Med College of Georgia
mi
from
Augusta, GA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Chicago
mi
from
Chicago, IL
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Kentucky
mi
from
Lexington, KY
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Franklin Square Hospital Center
mi
from
Baltimore, MD
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Franklin Square Hospital Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Cleveland Clinic
mi
from
Cleveland, OH
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
MetroHealth Med Ctr
mi
from
Cleveland, OH
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Hillcrest Hospital
mi
from
Cleveland, OH
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Hillcrest Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Case Western Reserve Univ
mi
from
Cleveland, OH
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Virginia
mi
from
Charlottesville, VA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/14/2012
Stanford University
mi
from
Stanford, CA
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/14/2012
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/17/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/17/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)
Status: Enrolling
Updated:  2/26/2013
Yale-New Haven Hospital Women's Center
mi
from
New Haven, CT
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)
Status: Enrolling
Updated: 2/26/2013
Yale-New Haven Hospital Women's Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Arizona Center for Cancer Care
mi
from
Glendale, AZ
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Arizona Center for Cancer Care
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Pinnacle Oncology
mi
from
Scottsdale, AZ
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Pinnacle Oncology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Wilshire Oncology Medical Group
mi
from
La Verne, CA
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
North County Oncology
mi
from
Oceanside, CA
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
North County Oncology
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Central Coast Medical Oncology
mi
from
Santa Maria, CA
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Central Coast Medical Oncology
mi
from
Santa Maria, CA
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Carolinas Medical Center/Blumenthal Cancer Center
mi
from
Charlotte, NC
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Carolinas Medical Center/Blumenthal Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Promedica Health System
mi
from
Toledo, OH
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Promedica Health System
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated:  2/27/2013
Chattanooga GYN Oncology
mi
from
Chattanooga, TN
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Status: Enrolling
Updated: 2/27/2013
Chattanooga GYN Oncology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated:  3/5/2013
Mayo Clinic
mi
from
Phoenix, AZ
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated: 3/5/2013
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated:  3/5/2013
Department of Obstetrics and Gynecology, University of California, Irvine
mi
from
Orange, CA
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated: 3/5/2013
Department of Obstetrics and Gynecology, University of California, Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated:  3/5/2013
Horizon Oncology Center
mi
from
Lafayette, IN
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated: 3/5/2013
Horizon Oncology Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated:  3/5/2013
Ochsner Medical Center
mi
from
New Orleans, LA
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated: 3/5/2013
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated:  3/5/2013
Morristown Memorial Hospital
mi
from
Morristown, NJ
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated: 3/5/2013
Morristown Memorial Hospital
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated:  3/5/2013
Blumenthal Cancer Center - Main
mi
from
Charlotte, NC
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated: 3/5/2013
Blumenthal Cancer Center - Main
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated:  3/5/2013
Duke Univ Med Ctr
mi
from
Durham, NC
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated: 3/5/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated:  3/5/2013
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Status: Enrolling
Updated: 3/5/2013
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital
Status: Enrolling
Updated:  3/13/2013
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital
Status: Enrolling
Updated: 3/13/2013
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated:  4/24/2013
Karmanos Cancer Center
mi
from
Detroit, MI
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated: 4/24/2013
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated:  4/24/2013
The University of Oklahoma Health Science Center
mi
from
Oklahoma City, OK
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated: 4/24/2013
The University of Oklahoma Health Science Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated:  4/24/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Status: Enrolling
Updated: 4/24/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials